N. Abdisa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
N. Abdisa has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Asfaw Meressa
Armauer Hansen Research Institute
1 shared publication - B. Akele
Armauer Hansen Re- search Institute
1 shared publication - B. Girma
Armauer Hansen Research Institute
1 shared publication - Dereilo Bekere Belitibo
Traditional and Modern Medicine Research and Development Directorate, Armauer Hansen Research Institute, Addis Ababa, Ethiopia
1 shared publication - Gashaw Nigussie
Armauer Hansen Research Institute
1 shared publication - M. Kasahun
Armauer Hansen Research Institute
1 shared publication
Latest Publications
- Open Access
- 20 May 2025
- Published by Sechenov University in The BRICS Health Journal
- Vol. 2 (1) , 53-68
Multi-targeted molecular docking, pharmacokinetic analysis, and drug-likeness evaluation of alkaloids for anti-diabetic drug development
Diabetes mellitus is a global health challenge, particularly in low-income regions, leading to severe complications. Plant-derived alkaloids offer potential as alternatives to conventional therapies. This study evaluated 31 alkaloids for antidiabetic drug development through molecular docking, pharmacokinetics, and drug-likeness analyses. Four standard drugs (epalrestat, metformin, acarbose, glibenclamide) and four targets (aldose reductase, adenosine monophosphate-activated protein kinase, a-glucosidase, protein tyrosine phosphatase 1B) were used for computational simulations.Molecular docking revealed that alkaloids mahanimbine (-11.5 kcal/mol), echinulin (11.3 kcal/mol), coptisine (-10.9 kcal/mol), and groenlandicine (-9.7 kcal/mol) have substantial binding affinities against aldose reductase compared to epalrestat (-9.3 Kcal/mol). In contrast to metformin (-4.8 kcal/mol), coptisine, echinulin, sanguinarine, and groelandicine showed superior binding affinities against adenosine monophosphateactivated protein kinase. In comparison to acarbose (-8.4 Kcal/mol), coptisine (-9.7 Kcal/mol), sanguinarine (-9.3 Kcal/mol), mahanimbine (-8.9 Kcal/mol), and echinulin (-8.9 Kcal/mol) demonstrated better docking scores against a-glucosidase. Jatrorrhizine, coptisine, sanguinarine, mahanimbine and echinuline respectively demonstrated higher binding scores of 8.8, -7.5, -7.5 and -7.2 Kcal/mol against protein tyrosine phosphatase 1B than glibenclamide (-7.0 Kcal/mol). Most alkaloids adhered to Lipinski’s rule, except casuarine 6-O-a-glucoside and conophylline. Pharmacokinetics identified pinoline as highly bioavailable and central nervous system penetrant, while conophylline had poor bioavailability.The study concluded that alkaloids including mahanimbine, echinulin, coptisine, groenlandicine, sanguinarine, and jatrorrhizine show strong binding affinities and favorable pharmacokinetic properties, requiring further in vitro and in vivo studies for therapeutic validation
- 20 May 2025
- Published by Sechenov University in The BRICS Health Journal
- Vol. 2 (1) , 53-68
Open AccessMulti-targeted molecular docking, pharmacokinetic analysis, and drug-likeness evaluation of alkaloids for anti-diabetic drug development
Diabetes mellitus is a global health challenge, particularly in low-income regions, leading to severe complications. Plant-derived alkaloids offer potential as alternatives to conventional therapies. This study evaluated 31 alkaloids for antidiabetic drug development through molecular docking, pharmacokinetics, and drug-likeness analyses. Four standard drugs (epalrestat, metformin, acarbose, glibenclamide) and four targets (aldose reductase, adenosine monophosphate-activated protein kinase, a-glucosidase, protein tyrosine phosphatase 1B) were used for computational simulations.Molecular docking revealed that alkaloids mahanimbine (-11.5 kcal/mol), echinulin (11.3 kcal/mol), coptisine (-10.9 kcal/mol), and groenlandicine (-9.7 kcal/mol) have substantial binding affinities against aldose reductase compared to epalrestat (-9.3 Kcal/mol). In contrast to metformin (-4.8 kcal/mol), coptisine, echinulin, sanguinarine, and groelandicine showed superior binding affinities against adenosine monophosphateactivated protein kinase. In comparison to acarbose (-8.4 Kcal/mol), coptisine (-9.7 Kcal/mol), sanguinarine (-9.3 Kcal/mol), mahanimbine (-8.9 Kcal/mol), and echinulin (-8.9 Kcal/mol) demonstrated better docking scores against a-glucosidase. Jatrorrhizine, coptisine, sanguinarine, mahanimbine and echinuline respectively demonstrated higher binding scores of 8.8, -7.5, -7.5 and -7.2 Kcal/mol against protein tyrosine phosphatase 1B than glibenclamide (-7.0 Kcal/mol). Most alkaloids adhered to Lipinski’s rule, except casuarine 6-O-a-glucoside and conophylline. Pharmacokinetics identified pinoline as highly bioavailable and central nervous system penetrant, while conophylline had poor bioavailability.The study concluded that alkaloids including mahanimbine, echinulin, coptisine, groenlandicine, sanguinarine, and jatrorrhizine show strong binding affinities and favorable pharmacokinetic properties, requiring further in vitro and in vivo studies for therapeutic validation